Bioporto A/S
F:2P4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bioporto A/S
F:2P4
|
DK |
|
Archos SA
LSE:0OI0
|
FR |
|
AstraZeneca PLC
NYSE:AZN
|
UK |
|
K
|
Karoon Energy Ltd
SWB:LBL
|
AU |
|
G
|
Geron Corp
LSE:0IV3
|
US |
|
Owl Rock Capital Corp
F:1D6
|
US |
|
Nufarm Ltd
ASX:NUF
|
AU |
|
M
|
Mayr Melnhof Karton AG
LSE:0NZ7
|
AT |
|
H
|
Honeywell International Inc
DUS:ALD
|
US |
|
F
|
Freeport-McMoRan Inc
XMUN:FPMB
|
US |
|
Wildcat Petroleum PLC
LSE:WCAT
|
UK |
Bioporto A/S
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
